Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M et al.
Expert Opinion on Therapeutic Targets, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
32958805 (PubMed )
Supplement: 41598_2020_72404_MOESM2_ESM.xlsx › ClinVar
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.
Zhang Y et al.
Molecular Cancer, 2018
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS et al.
Cancer Research, 2010
Select a paper to view details